GlassScriptPhysician profile
Jenny Steben
NPI 1962134536
$1,219.87
in general payments reported to CMS, 2019-2025
13 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $61.23 · 2023: $430 · 2024: $500 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $567.79 | 2023-2024 | Qelbree, Qelbree |
| Revance Therapeutics, INC. | $173.96 | 2025 | Daxxify |
| Otsuka America Pharmaceutical, INC. | $98.58 | 2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $63.01 | 2023 | |
| Janssen Pharmaceuticals, INC | $61.80 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.23 | 2022 | |
| Idorsia Pharmaceuticals US INC | $53.69 | 2023 | Quviviq |
| Mdd US Operations, LLC | $39.26 | 2025 | Qelbree |
| Alkermes, INC. | $29.21 | 2023 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $21.84 | 2023 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $18.86 | 2023 | Austedo |
| Novo Nordisk INC | $15.53 | 2025 | Ozempic |
| Corium, LLC | $15.11 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Steben listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.